INTRODUCTION: Parenteral OKT3 is used to treat transplant rejection and a humanized anti-CD3 Mab has shown positive clinical effects in new onset diabetes. Oral administration of anti-CD3 has not been tested in humans, but suppresses autoimmunity in animal models. Beta-glucosylceramide enhances NKT cell and regulatory T cell activity and enhances the effects of oral anti-CD3 in animals. MATERIALS AND METHODS: Fifteen healthy volunteers (three per group) received orally administered OKT3 over a dose range of 0.2 to 5.0 mg daily with or without beta-glucosylceramide 7.5 mg for 5 days. Safety and immune parameters were measured on days 5, 10, and 30. RESULTS AND DISCUSSION: Oral OKT3 enhanced T cell proliferation, suppressed Th1 and Th17 responses by 43% and 41%, respectively, increased TGF-beta/IL-10 expression and decreased IL-23/IL-6 expression by dendritic cells, and affected the IgG repertoire as measured by antigen arrays. Co-administration of oral beta-glucosylceramide induced similar effects. No side effects were observed and no subjects developed human anti-mouse antibodies. CONCLUSION: These findings demonstrate that oral anti-CD3 monoclonal antibody is safe and biologically active in humans and presents a new avenue for the treatment of autoimmune diseases.
INTRODUCTION: Parenteral OKT3 is used to treat transplant rejection and a humanized anti-CD3 Mab has shown positive clinical effects in new onset diabetes. Oral administration of anti-CD3 has not been tested in humans, but suppresses autoimmunity in animal models. Beta-glucosylceramide enhances NKT cell and regulatory T cell activity and enhances the effects of oral anti-CD3 in animals. MATERIALS AND METHODS: Fifteen healthy volunteers (three per group) received orally administered OKT3 over a dose range of 0.2 to 5.0 mg daily with or without beta-glucosylceramide 7.5 mg for 5 days. Safety and immune parameters were measured on days 5, 10, and 30. RESULTS AND DISCUSSION: Oral OKT3 enhanced T cell proliferation, suppressed Th1 and Th17 responses by 43% and 41%, respectively, increased TGF-beta/IL-10 expression and decreased IL-23/IL-6 expression by dendritic cells, and affected the IgG repertoire as measured by antigen arrays. Co-administration of oral beta-glucosylceramide induced similar effects. No side effects were observed and no subjects developed human anti-mouse antibodies. CONCLUSION: These findings demonstrate that oral anti-CD3 monoclonal antibody is safe and biologically active in humans and presents a new avenue for the treatment of autoimmune diseases.
Authors: E Zigmond; S Preston; O Pappo; G Lalazar; M Margalit; Z Shalev; L Zolotarov; D Friedman; R Alper; Y Ilan Journal: Gut Date: 2007-01 Impact factor: 23.059
Authors: Wolfgang Hueber; Brian A Kidd; Beren H Tomooka; Byung J Lee; Bonnie Bruce; James F Fries; Grete Sønderstrup; Paul Monach; Jan W Drijfhout; Walther J van Venrooij; Paul J Utz; Mark C Genovese; William H Robinson Journal: Arthritis Rheum Date: 2005-09
Authors: Maya Margalit; Samir Abu Gazala; Samir Abu Ghazala; Ruslana Alper; Eran Elinav; Athalia Klein; Victoria Doviner; Yoav Sherman; Barbara Thalenfeld; Dean Engelhardt; Elazar Rabbani; Yaron Ilan Journal: Am J Physiol Gastrointest Liver Physiol Date: 2005-06-23 Impact factor: 4.052
Authors: Hirofumi Ochi; Michal Abraham; Hiroki Ishikawa; Dan Frenkel; Kaiyong Yang; Alexandre S Basso; Henry Wu; Mei-Ling Chen; Roopali Gandhi; Ariel Miller; Ruth Maron; Howard L Weiner Journal: Nat Med Date: 2006-05-21 Impact factor: 53.440
Authors: Simon W F Milling; Ulf Yrlid; Chris Jenkins; Claire M Richards; Neil A Williams; Gordon MacPherson Journal: Eur J Immunol Date: 2007-01 Impact factor: 5.532
Authors: Daniel R Getts; Aaron J Martin; Derrick P McCarthy; Rachael L Terry; Zoe N Hunter; Woon Teck Yap; Meghann Teague Getts; Michael Pleiss; Xunrong Luo; Nicholas J C King; Lonnie D Shea; Stephen D Miller Journal: Nat Biotechnol Date: 2012-11-18 Impact factor: 54.908